低分子藥物研發市場，各治療領域，流程/不同階段，各地區- 規模，佔有率，展望，機會分析，2022年～2028年

市場力學

慢性病的高發病率、對小分子藥物的需求增加、對小分子藥物發現的日益關注、合同組織數量的增加以及研發活動的增加，預計將推動全球小分子藥物發現市場的增長。

本調查的主要特徵

• 本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球低分子藥物研發市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
• 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
• 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
• 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球低分子藥物研發市場的主要參與者之企業簡介。
• 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 全球低分子藥物研發市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以透過全球低分子藥物研發市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查目的與前提條件

• 調查目的
• 前提條件
• 簡稱的說明

第2章 市場展望

• 報告內容
  • 市場定義和範圍
• 摘要整理
  • 市場概述:各治療領域
  • 市場概述:流程/不同階段
  • 市場概述:各地區
• 連貫機遇地圖(COM)

第3章 市場動態，法規，及趨勢的分析

• 市場動態
  • 全球慢性病患病率上升
  • 嚴格的法規和高昂的藥物開發成本
  • 全球對小分子藥物的需求上升
• 影響分析
• 主要的焦點
• 法規方案
• 產品上市/核准
• PEST分析
• PORTER的分析
• 合併·收購情景

第4章 低分子藥物研發的全球市場-冠狀病毒(COVID-19)疫情的影響

• COVID-19流行病學的特徵
• 供給面和需求面的分析
• 經濟衝擊

第5章 低分子藥物研發的全球市場，各治療領域，2017年～2028年

• 腫瘤學
• 中樞神經系統
• 循環系統系
• 呼吸系統
• 代謝異常
• 消化器官
• 其他治療領域

第6章 低分子藥物研發的全球市場(流程/不同階段):2017年～2028年

• 目標ID/驗證
• 命中生成和選擇
• 領導的鑑定
• 領導的最佳化

第7章 低分子藥物研發的全球市場，各地區，2017年～2028年

• 北美
• 歐洲
• 亞太地區
• 南美
• 中東·非洲
• 全球其他地區

第8章 競爭情形

• Pfizer Inc.
• Novartis
• Teva Pharmaceuticals
• Merck KgaA
• Johnson & Johnson
• GlaxoSmithKline PLC
• Gilead Sciences Inc.
• AstraZeneca
• Immunocure Inc.
• Acacia Pharma Gr
• 4SC AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• 21st Century Therapeutics Inc.
• Takeda Pharmaceutical Industries Ltd.

第9章 章節

• 調查手法
• 關於出版社

Small molecule drugs have represented some of the crucial blockbusters in the history of the pharmaceutical industry. Defined as any organic compound with low molecular weight, small molecule drugs have some distinct advantages as therapeutics. Small molecule drugs capable of modulating biochemical processes to diagnose, treat, and prevent diseases. Small molecule drugs are the mainstay of medicine, representing around 90 percent of all approved medicines and 75 percent of all new medicines approved in the U.S. in 2020.

Market Dynamics:

High prevalence of chronic diseases, increase in demand for small molecule drugs, rise in focus on small molecule drug discovery, increasing number of contract organizations, and increase in research and development activities are some major factors expected to augment the growth of the global small molecule drug discovery market.

In July 2022, RxCelerate revealed details of a new small molecule discovery platform, named RxNfinity, which leverages machine learning, in silico structure modeling and combinatorial chemistry in a novel workflow that offers significant advantages over the current generation of tools to identify small molecule drugs against a wide range of protein targets.

In July 2022, Dotmatics announced the release of its Small Molecule Drug Discovery Solution, an integrated scientific research and development platform with pre-configured workflows and expanded data management capabilities. The new solution will help companies innovate more easily by leveraging best practices derived from Dotmatics' 15+ years of experience supporting small molecule drug discovery.

Key features of the study:

• This report provides in-depth analysis of the global small molecule drug discovery market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global small molecule drug discovery market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Teva Pharmaceuticals, Merck KgaA, Johnson & Johnson, GlaxoSmithKline PLC, Gilead Sciences Inc., AstraZeneca, Immunocure Inc., Acacia Pharma Gr, 4SC AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, 21st Century Therapeutics, Novartis, Pfizer Inc., and Takeda Pharmaceutical Industries Ltd., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global small molecule drug discovery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule drug discovery market.

Detailed Segmentation:

• Global Small Molecule Drug Discovery Market, By Therapeutic Area:
  • Oncology
  • Central Nervous System
  • Cardiovascular
  • Respiratory
  • Metabolic Disorders
  • Gastrointestinal
  • Other Therapeutic Areas
• Global Small Molecule Drug Discovery Market, By Process/Phase:
  • Target ID/Validation
  • Hit Generation and Selection
  • Lead Identification
  • Lead Optimization
• Global Small Molecule Drug Discovery Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa
• Company Profiles:
  • Teva Pharmaceuticals
  • Merck KgaA
  • Johnson & Johnson
  • GlaxoSmithKline PLC
  • Gilead Sciences Inc.
  • AstraZeneca
  • Immunocure Inc.
  • Acacia Pharma Gr
  • 4SC AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • 21st Century Therapeutics Inc.
  • Novartis
  • Pfizer Inc.
  • Takeda Pharmaceutical Industries Ltd.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapeutic Area
  • Market Snapshot, By Process/Phase
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of chronic diseases worldwide
  • Stringent regulations and high cost of drug development
  • Rise in demand for small molecule drugs worldwide
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Small Molecule Drug Discovery Market - Impact of Coronavirus (Covid-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Small Molecule Drug Discovery Market, By Therapeutic Area, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Central Nervous System
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Cardiovascular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Respiratory
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Metabolic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Gastrointestinal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Other Therapeutic Areas
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Small Molecule Drug Discovery Market, By Process/Phase, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Target ID/Validation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Hit Generation and Selection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Lead Identification
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Lead Optimization
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Small Molecule Drug Discovery Market, By Geography, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Rest of World
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KgaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Immunocure Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Acacia Pharma Gr
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• 4SC AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim GmbH
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• 21st Century Therapeutics Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us